文献速递乳腺癌

T-DXd 最佳确认缓解与 HER2 阳性转移性乳腺癌生物标志物汇总分析

Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03.
PubMed 文献 · Ann Oncol · 2025-11-18

该探索性汇总分析纳入 DESTINY-Breast01/02/03 中接受 T-DXd 5.4 mg/kg 的 834 例 HER2 阳性转移性乳腺癌患者。最佳确认缓解为 CR 者 125 例(15.0%)、PR 者 477 例(57.2%)、无缓解者 232 例(27.8%)。缓解者尤其 CR 者 PFS 与 OS 延长,CR 者 24 个月 PFS 率 77.8%、36 个月 OS 率 88.6%。

要点

  • T-DXd 治疗后达到 CR 者 24 个月 PFS 率 77.8%、36 个月 OS 率 88.6%。
  • PR 者对应 24 个月 PFS 率 46.3%、36 个月 OS 率 54.0%。
  • 无缓解者 24 个月 PFS 率 20.6%、36 个月 OS 率 35.9%。

核心结论

  • 对 T-DXd 达到客观缓解尤其 CR 的患者,中位 PFS 与 OS 延长。
  • 结果支持 T-DXd 用于广泛 HER2 阳性转移性乳腺癌人群,包括疾病负荷较低者。
  • 对 T-DXd 无缓解者存在未满足的医疗需求,需研究更有效方案。

研究设计与样本

  • 探索性汇总分析,汇总 DESTINY-Breast01/02/03 中接受 T-DXd 5.4 mg/kg 的患者。
  • 共 834 例可评估缓解,按最佳确认缓解分组分析基线特征与长期结局。
  • 缓解评估采用(盲态)独立中心审评及 RECIST v1.1。

主要发现

  • CR 125 例(15.0%)、PR 477 例(57.2%)、无缓解 232 例(27.8%)。
  • CR 者转移阶段既往方案中位数为 2,PR 与无缓解者为 3。
  • CR 者内脏病变及基线脑或骨转移较少见。
  • CR 者严重不良事件、T-DXd 停药及间质性肺病/肺炎发生率数值上更低。
  • 探索性生物标志物分析显示缓解者基线 HER2 血浆拷贝数数值更高、ESR1 表达与突变频率更低、ctDNA 水平更低。

关键数值与推荐

  • CR 者 24 个月 PFS 率 77.8%、36 个月 OS 率 88.6%。
  • PR 者 24 个月 PFS 率 46.3%、36 个月 OS 率 54.0%。
  • 无缓解者 24 个月 PFS 率 20.6%、36 个月 OS 率 35.9%。

临床怎么用

  • T-DXd 可用于广泛 HER2 阳性转移性乳腺癌人群,包括疾病负荷较低者。
  • 最佳确认缓解尤其 CR 与更优长期生存相关,可作为预后参考。
  • 对 T-DXd 无缓解者需关注并探索更有效治疗策略。

局限性

  • 为探索性汇总分析,非预设统计检验。
  • 生物标志物分析为探索性,结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Objective response rates in the DESTINY-Breast01/02/03 trials, which evaluated trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC), were 62%/70%/79%, respectively. PATIENTS AND METHODS: This exploratory pooled analysis investigated associations between best confirmed response to T-DXd and baseline characteristics/long-term outcomes in patients who received T-DXd 5.4 mg/kg in DESTINY-Breast01/02/03. Endpoints included best confirmed response per (blinded) independent central review [(B)ICR] using RECIST v1.1, progression-free survival (PFS) by (B)ICR, overall survival (OS), safety, and biomarker analyses of expression levels/alterations of genes relevant to HER2-positive mBC or T-DXd activity. RESULTS: A total of 834 patients who received T-DXd in DESTINY-Breast01/02/03 were assessable for response; 125 (15.0%) experienced complete response (CR), 477 (57.2%) experienced partial response (PR), and 232 (27.8%) were considered non-responders (stable disease/progressive disease). The median number of prior regimens in the metastatic setting was two for patients with CR versus three for patients with PR and non-responders; visceral disease and baseline brain or bone metastases were less frequently observed in patients with CR. The 24-month PFS rates in patients with CR, PR, and no response, respectively, were 77.8%, 46.3%, and 20.6%, and 36-month OS rates were 88.6%, 54.0%, and 35.9%. Rates of serious adverse events, T-DXd discontinuation, and interstitial lung disease/pneumonitis were numerically lower in patients with CR. In exploratory biomarker analyses, responders had tumors with numerically higher HER2 plasma copy number, lower ESR1 gene expression and ESR1 mutation frequency, and lower circulating tumor DNA levels at baseline. CONCLUSIONS: Patients with objective response to T-DXd, particularly those with CR, showed prolonged median PFS and OS. These results support T-DXd use across broad patient groups with HER2-positive mBC, including those with lower disease burden. Patients whose disease does not respond to T-DXd represent an unmet medical need, and research into more effective treatment approaches for these patients is warranted.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Saura C, Cortés J, Modi S, et al. Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03. Ann Oncol. 2025. PMID: 41260262. doi:10.1016/j.annonc.2025.11.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。